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Abstract
Oocyte cryopreservation is one of the state-of-art technologies in human repro-
ductive medicine, which brings opportunities for women to preserve their fertility. In 
the present study, we analyzed the efficiency and outcomes of 8 years’ autologous egg 
cryopreservation: Frozen oocytes were warmed from 120 cycles and oocyte survival, 
fertilization, blastocyst development, clinical pregnancy, embryo implantation, live 
birth rates and birth weights were collected based on the patients’ ages of <35, 35–37 
and > 37 years old. The details of oocyte cryopreservation and the efficiency were 
further analyzed based on different patient categories. During the study period, 849 
oocytes from 120 cycles were warmed. Oocyte survival, fertilization, and blastocyst 
development were not affected by women’s ages at the time of cryopreservation. 
However, number of patients without blastocyst formation was significantly 
(P < 0.05) higher in patients >37 years old (31.2%) than that in patients <35 years 
old (13.1%). Higher live birth rates were observed in patients <35 (51.1%) and 35–37 
(46.7%) years old than in patients >37 years old (28.6%) after fresh embryo transfer. 
Some patients did not have blastocysts mainly due to low fertilization by poor sperm 
or small number of oocytes warmed. These results indicate that the efficiency of 
oocyte cryopreservation, evaluated by live birth and embryo implantation rates is 
affected by women’s age, number of oocytes warmed and sperm quality.
Keywords: Oocyte cryopreservation, Fertility preservation, Fresh embryo transfer, 
Frozen embryo transfer, Implantation
1. Introduction
Oocyte cryopreservation is one of the state-of-art technologies in human 
assisted reproductive technologies (ART), which provides opportunities for women 
to preserve their fertility. Recently, the demand for oocyte cryopreservation has 
increased significantly, especially in women who want to delay childbearing for 
medical or no medial indications [1–9].
It has been reported that survival, fertilization, embryo development and 
pregnancy rates of cryopreserved/warmed human oocytes are similar to those of 
fresh oocytes, especially in young women and oocyte donors [10, 11]. The rates 
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of chromosomal abnormalities (embryonic aneuploidies), birth defects, or 
developmental deficits in offspring born from cryopreserved oocyte in vitro 
fertilization (IVF) were similar with those from fresh oocyte IVF [12]. However, 
fewer blastocysts were observed when cryopreserved oocytes were used for 
IVF as compared with fresh oocytes in patients who used autologous oocytes 
[13]. Furthermore, large clinical data reported by the Society for Assisted 
Reproductive Technology (SART) in USA indicated that fresh donor oocytes 
produced significantly higher live birth rate than cryopreserved donor oocytes 
[14] and the equivalency between fresh and cryopreserved oocytes still need 
more data to support [15].
As a new technology in human IVF, oocyte cryopreservation is still a challenge 
for IVF laboratories as it adds more laboratory manipulations on oocytes includ-
ing cryopreservation and warming. Furthermore, the optimal time for oocytes to 
be cryopreserved after retrieval and for oocytes to be inseminated after warming 
may be different between patients. Therefore, differences in laboratory protocols 
may make the efficiency different and a case-specific protocol may be necessary to 
obtain the best outcome. More information remains to be collected whether oocyte 
cryopreservation will be widely offered to healthy women at any age as an approach 
to preserve fertility and delay childbirth [16, 17].
More women would like to give birth in their late 30s [4, 18]. However, women’s 
fertility dramatically declines when they reach their late 30s, and further declines 
in their early 40s [4]. This phenomenon increases the demand for women to 
preserve their fertility by oocyte cryopreservation before their fertility declines [4, 
18]. Although fertility preservation could benefit women who have hematologic 
diseases, breast cancer, some pelvic cancers and systematic diseases requiring 
chemotherapy, radiotherapy or bone marrow transplantation [2, 3, 19, 20], most 
users of this technology are healthy women who want to postpone childbearing  
[2, 3, 7, 8, 17, 18, 21, 22].
On the other hand, oocyte cryopreservation is offered not only to women for 
fertility preservation [7, 8, 21–23], it has also been offered to donor banks [24, 25], 
IVF patients as a backup technology. For example, in cases where semen sample 
may not be available on oocyte retrieval day, no motile sperm found in a semen 
sample, or there are not enough motile sperm for insemination of all oocytes 
retrieved. Some patients may produce a high number of oocytes and do not want to 
inseminate all, and some patients may want a limited number of oocytes to be fertil-
ized [23]. Therefore, oocyte cryopreservation is required under various situations. 
Accordingly, the analysis of efficiency of clinical outcomes with cryopreserved 
oocytes becomes difficult.
The efficiency of human oocyte cryopreservation has been widely studied in 
donor oocytes and most data were collected from fresh embryo transfer  
[10, 11, 14, 15]. However, as preimplantation genetic testing for aneuploidies 
(PGT-A) and other genetic testing are very common in human IVF, it is required 
that biopsied embryos for testing are cryopreserved for later frozen embryo transfer 
(FET). Although cryopreservation by vitrification of human embryos from fresh 
oocytes does not affect embryo implantation [26–28], there is still no published 
evidence to address whether cryopreservation of embryos from frozen/warmed 
oocytes disturb embryo implantation or these embryos have a similar implantation 
as fresh embryos. Therefore, in the present study, we compared fresh blastocyst 
transfer and frozen/warmed blastocyst transfer to examine whether double cryo-
preservation (both oocyte and blastocyst cryopreservation) has a similar efficiency 
as single cryopreservation (oocyte cryopreservation) based on women’s ages at the 
time of oocyte cryopreservation.
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2. Methods
2.1 Ethics approval and consent to participate
All patients undergoing oocyte cryopreservation, warming for IVF, embryo  
culture, and embryo transfer signed informed consents for all laboratory and 
clinical procedures. All procedures were approved by Houston Fertility Institute’s 
research and clinical committee. The data were retrospectively collected from the 
medical records and patients’ information were not included in the data presenta-
tion, so the IRB was waived for this study.
2.2 Patients and data collection
Autologous oocyte cryopreservation was assessed in women whose oocyte 
cryopreservation and warming were performed between 2009 and 2017. Women’s 
age at the time of oocyte cryopreservation was divided into 3 groups, <35, 35–37 
and > 37 years old. Based on these age groups, data were compared between fresh 
blastocyst transfer and frozen/warmed blastocyst transfer.
There were mainly three reasons for patients to cryopreserve their oocytes: 1) all 
oocytes were cryopreserved because there was no motile sperm or no semen sample 
being collected at the time of oocyte retrieval; 2) partial oocytes were cryopreserved 
because no enough motile sperm was found to inseminate all of the oocytes, or patients 
required to inseminate a portion of oocytes and purposely required to cryopreserve 
remaining oocytes; and 3) all oocytes were cryopreserved for single women for fertility 
preservation. Therefore, the data were further analyzed based on these three categories.
2.3 Oocyte cryopreservation, warming and insemination
Oocyte cryopreservation and warming were based on the procedures previously 
reported [11] by using commercial vitrification and warming kits (Fujifilm-Irvine 
Scientific, CA, USA). Briefly, for cryopreservation, matured oocytes were vitrified 
4–5 hours after retrieval with initial equilibration of the oocytes in equilibration 
solution (ES) for 9 mins, and then in vitrification solution (VS) for 90 seconds until 
vitrification in Cryotop.
For warming, Cryotops were removed from liquid nitrogen and the tips with 
oocytes were quickly placed in 1 ml thawing solution (TS) at 37°C for 1 min. 
Oocytes were then transferred to 0.5 ml dilution solution (DS) for 3 min and then to 
a 0.5 ml washing solution (WS) for 10 min with a solution change after 5 min. After 
warming, oocytes were washed in Global medium (IVFonline, CT, USA) supple-
mented with 10% serum protein substitute (SPS, IVFonline) and then cultured 
in the same medium until insemination. Oocyte survival was evaluated based on 
morphology after completion of the warming.
2.4  Insemination, fertilization assessment, embryo culture and fresh  
blastocyst transfer
All oocytes were inseminated by intracytoplasmic sperm injection (ICSI) 
2–3 hours after warming. We chose this time for ICSI as it has been reported that 
most functions, such as meiotic spindle recovery, mitochondria activity and ATP 
level recovery in frozen/warmed oocytes, take about 2–3 hours after warming 
[29–31] and it has been found that ICSI time (9 ± 2 h) after oocyte retrieval in the 
vitrified human oocytes does not affect clinical outcomes [32].
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Fertilization was examined 16–18 h after ICSI and normally fertilized 
zygotes were cultured in Global medium supplemented with 10% SPS at 37°C 
in a humidified atmosphere of 5.5% CO2, 6% O2 and balanced nitrogen until 
Day 7 (some patients’ embryo culture was extended to Day 7 if morula or early 
blastocysts were observed at Day 6). On Day 3, embryo cleavage status was 
examined, and all embryos that divided to two cells and above were considered 
as cleaved embryos and were transferred to freshly prepared culture medium. 
On Day 5, embryo development was evaluated and the best 1 or 2 embryos were 
transferred.
2.5 Blastocyst biopsy for PGT-A
Blastocysts were biopsied at Days 5, 6 and 7 for PGT-A in some patients based on 
patients’ requests and FET were performed in these patients if there were euploid 
blastocysts. After biopsy, blastocysts were vitrified individually, and biopsied 
samples were analyzed with DNA microarray or next generation sequencing by 
commercial genetic testing companies.
2.6 Blastocyst vitrification, warming and transfer
Blastocysts were vitrified and warmed using commercial vitrification and 
warming kits (Fujifilm-Irvine Scientific). For vitrification, both ES and VS were 
warmed in original vials at 37°C for at least 30 min before use. Briefly, collapsed 
blastocysts by a laser pulse were equilibrated in 100 μl drop (without oil cover) of 
ES for 2 min, and then 45 seconds in 100 μl drop (without oil cover) of VS (both 
steps were performed on a 37°C warming stage) before loading to vitrification 
devices. The devices were then immersed to liquid nitrogen for vitrification and all 
samples were stored in liquid nitrogen until warming for FET.
For warming, blastocysts were exposed to a TS at 37°C for 1 min, transferred 
to a DS for 3 min and finally to a WS for 10 min with a solution change after 5 min 
at room temperature. After completion of the warming process, blastocysts were 
cultured in Global medium supplemented with 10% SPS for 2–4 h before trans-
fer. For blastocyst transfer, we selected the best quality of blastocyst for transfer 
regardless of Day 5, 6 or 7. However, if the blastocysts had the same quality, Day 5 
blastocyst is preferred than Days 6 and 7 blastocysts. If embryos after PGT-A were 
transferred, we used same embryo selection criteria but only euploid blastocysts 
were transferred.
2.7 Patient preparation for fresh and frozen/warmed blastocyst transfer
All patients for embryo transfer received estradiol orally and transvaginally. 
Intramuscular administration of progesterone oil was initiated at about Day 14 of 
estradiol treatment. Endometrium thickness was measured on the day of proges-
terone administration. Embryo transfer occurred on the sixth or seventh day of 
progesterone administration and progesterone was continued until the first serum 
β-hCG test two weeks after transfer. Pregnancy was assessed 14 days after embryo 
transfer by a serum β-hCG assay. When the β-hCG was >5 mIU/ml, the patients 
were regarded as having a biochemical pregnancy and pregnancies were supported 
by continued estradiol and progesterone. Four weeks after embryo transfer, when 
a gestational sac and a heartbeat appeared ultrasonographically, the patients were 
diagnosed as having a clinical pregnancy. Live birth rates were calculated based on 
healthy baby delivery per transfer.
5
Efficiency of Autologous Egg Cryopreservation: Eight Years’ Experiences and Clinical Outcomes
DOI: http://dx.doi.org/10.5772/intechopen.98675
2.8 Statistical analysis
Interval data was analyzed by one-way analysis of ANOVA. The differences 
between groups were compared with chi square test. If the P value was less 0.05, the 
difference was considered to be statistically significant.
3. Results
As shown in Figure 1, 849 oocytes from 120 patients were warmed, 61 cycles 
were from women <35 years old, 27 cycles were from women 35–37 years old, and 
32 cycles were from women >37 years old. The resulting blastocysts were either 
fresh transfer (74 cycles) at Day 5 or cryopreserved at Day 5–7 (23 cycles) for later 
FET Twenty-two patients had frozen all blastocysts due to PGT-A, and one patient 
(45 years old) had plan for fresh blastocyst transfer but did not have blastocyst 
at Day 5, so blastocyst transfer was canceled. However, one embryo developed to 
blastocyst at Day 7, so it was frozen and then processed for frozen/warmed blasto-
cyst transfer.
A total of 67 blastocysts from 22 patients were biopsied and 55.2% (37) blas-
tocysts were euploid after PGT-A. Euploid blastocysts in 16 patients and a Day 7 
blastocyst without PGT-A in 1 patient were transferred in FET cycles.
Twenty-three cycles did not have embryo transfer due to no blastocyst forma-
tion, including no fertilization, no cleavage or arrested embryo development before 
blastocyst stage.
Women’s ages at the time of oocyte cryopreservation on post-warming outcomes 
were shown in Table 1. It was found that average numbers of oocytes warmed 
Figure 1. 
Diagram of patient population and cycle information. Patients were grouped based on ages of <35, 35–37 
or > 37 years old at the time of oocyte cryopreservation. Only the first embryo transfer (either fresh or FET) was 
included in the data analysis.
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(7.2 ± 6.0, 7.2 ± 5.5 and 6.7 ± 3.7, respectively), proportions of oocytes survived 
(93.4, 90.8 and 94.9%, respectively), fertilized (71.2, 72.3 and 73.0%, respectively), 
cleaved (95.2, 92.2 and 94.0%, respectively) and developed to blastocysts (56.8, 
54.2 and 49.3%, respectively) were similar (P > 0.05) among patients <35, 35–37 
and > 37 years old. However, cancelation rates, which were determined by no avail-
able blastocyst for transfer were significantly (P < 0.05) higher in patients >37 years 
old (31.2%) than in patients <35 years old (13.1%).
As significant differences in the cancelation rates were present in the three age 
groups, we further analyzed the detailed reasons of the cancelation. As shown in 
Table 2, it was found that oocyte survival after warming did not cause any cancel-
ation, and all patients had survived oocytes after warming. However, cancelation 
was observed in 30.4% (7/23) patients without fertilization after ICSI, in 8.7% 
Age <35 35–37 >37
Cases 61 27 32
No. of oocytes warmed 439 195 215
Mean No. of oocytes 7.2 ± 6.0 7.2 ± 5.5 6.7 ± 3.7
No. of oocytes survived (%) 410 (93.4) 177 (90.8) 204 (94.9)
No. of oocytes fertilized (%) 292 (71.2) 128 (72.3) 149 (73.0)
No. of oocytes cleaved (%) 278 (95.2) 118 (92.2) 140 (94.0)
No. of blastocysts (%) 158 (56.8) 64 (54.2) 69 (49.3)
No. of patients without blastocysts (%)* 8 (13.1)a 5 (18.5) 10 (31.2)b
*No. of patients without blastocysts includes all cases in which oocytes were not fertilized after ICSI, fertilized oocytes 
did not cleave, and cleaved embryos did not develop to blastocyst stage.
abValues are significantly different with different superscripts in the same row, P < 0.05.
Table 1. 
Women’s ages at the time of oocyte cryopreservation on post-warming laboratory outcomes.
Age <35 35–37 >37 Total
No. of cases with no survived oocyte after 
warming (%)
0 (0) 0 (0) 0 (0) 0 (0)
No. of cases with no fertilization after ICSI (%) 5 (62.5) 1 (20) 1 (10) 7 (30.4)
No. of cases with no cleavage after  
fertilization (%)
0 (0) 1 (20) 1 (10) 2 (8.7)
No. of cases with no blastocyst (%) 3 (37.5) 3 (60) 8 (80) 14 (60.9)
*No statistical differences were found between different age groups, P > 0.05.
Table 2. 
Detailed reason analysis of patients without blastocysts*.
No. of oocytes warmed Patients’ age Total
<35 35–37 >37
1–3 4 (50) 1 (20) 3 (30) 8 (34.8)
4–8 3 (37.5) 4 (80) 5 (50) 12 (52.1)
>8 1 (12.5) 0 (0) 2 (20) 3 (13.0)
*No statistical differences were found between different age groups, P > 0.05.
Table 3. 
Relationship between number of oocytes warmed and no blastocyst formation*.
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(2/23) patients without embryo cleavage and in 60.9% (14/23) patients without 
blastocyst development that was the main reason of cancelation. However, no 
statistical differences were found among three age groups.
Age <35 35–37 >37
No. of transfer 45 15 14








Mean No. of embryos transferred 1.6 ± 0.6 1.8 ± 0.5 1.71 ± 0.47
Implantation rate (%) 39.2 29.6 25.0








Mean birth weight (g) 3037 ± 805 3462 ± 674 2856 ± 516
*P > 0.05 in all comparison groups within the same age group between transfers (only fresh embryo transfers were 
compared).
Table 4. 
Women’s ages at the time of oocyte cryopreservation on post-warming clinical outcomes*.
Patient categories All oocyte freezing 




All oocyte freezing for 
fertility preservation***
No. of cases 37 67 16
Age 35.5 ± 5.7 33.4 ± 4.5 36.8 ± 3.7
No. of oocytes 
warmed
363 336 150
Mean No. of oocytes 
warmed
9.8 ± 5.8a 5.0 ± 3.7b 9.4 ± 4.4a
No. of oocyte survived 
(%)
339 (93.4) 307 (91.3) 145 (96.7)
No. of oocyte fertilized 
(%)
251 (74.0)ab 207 (67.4)b 111 (76.6)a
No. of oocyte cleaved 
(%)
235 (93.6) 194 (93.7) 107 (96.4)
No. of blastocysts (%) 132 (56.2) 112 (57.7) 47 (43.9)
No. of cancelation (%) 5 (13.5) 14 (21.8) 4 (8.7)
No. of transfers 32 50 9
Mean No. embryos 
transferred
1.4 ± 0.8 1.6 ± 0.5 1.7 ± 0.5
No. of clinical 
pregnancy (%)
17 (53.1)ab 18 (36)b 8 (88.9)a
No. of live birth (%) 15 (46.9)ab 18 (36)b 7 (77.8)a
Implantation rate (%) 21/53 (39.6)ab 21/79 (26.6)a 11/15 (73.3)b
abP < 0.05 at least in the same row with different superscripts.
*Semen samples were not able to collect or samples did not have motile sperm, all oocytes were frozen.
**Semen sample had motile sperm but sperm number was not enough to fertilize all of the oocytes or patients wanted 
to fertilize partial oocytes and to freeze the remaining oocytes.
***All oocytes were frozen for fertility preservation.
Table 5. 
Patient categories for oocyte cryopreservation and clinical outcomes.
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As shown in Table 3, when oocyte number (1–3, 4–8 and > 8 oocytes per warm-
ing cycle) and cancelation were analyzed, it was found that no blastocyst formation 
was found in all groups: 34.8% with 1–3 oocytes, 52.1% with 4–8 oocytes and 13.0% 
with >8 oocytes. There is increased tendency that less cancelation was observed if 
more than 8 oocytes were warmed. However, no statistical differences were found 
among three age groups or three oocyte number groups.
As shown in Table 4, when fresh blastocyst transfers were compared in terms 
of clinical pregnancy, mean no. of embryo transferred, embryo implantation, live 
birth and birth weight in three age groups, there were no statistical difference be 
observed although the rates were lower in the patients at age of >37. FET cases in 
each age group were small (7, 3 and 7 cases for age of <35, 35–37 and > 37, respec-
tively), the clinical pregnancies (2, 2 and 2 cases, respectively) and live births (2, 2 
and 2 cases, respectively) were not included in the comparisons.
When the data were analyzed based on three categories of patients for oocyte 
cryopreservation, as shown in Table 5, it was found that the number of oocytes 
warmed and reasons for oocyte cryopreservation had significant impact on clinical 
outcomes. The patients who had partial oocyte cryopreservation had significantly 
(P < 0.05) fewer oocytes to be warmed (5.0 ± 3.7) as comparing with patients who 
had all oocyte cryopreservation, including patients for backup oocyte cryopreser-
vation (9.8 ± 5.8) and women for fertility preservation (9.4 ± 4.4). There was no 
statistical difference in the oocyte survival (91.3–96.7%) among three categories, 
however, significantly (P < 0.05) lower rates in fertilization (67.4 vs. 76.6%), clinical 
pregnancy (36.0 vs. 88.9%), live birth (36.0 vs. 77.8%) and embryo implantation 
(26.6 vs. 73.3%) were observed in patients with partial oocyte cryopreservation as 
compared with women for fertility preservation. Other comparisons, including 
women’s age, cleavage, blastocyst formation, cancelation, and mean no. of embryos 
transferred in all groups did not show statistical differences.
4. Discussion
It has been demonstrated that oocyte cryopreservation does not compromise in 
vitro development and pregnancy rates as compared with fresh oocytes [1, 9–12]. 
Because of its reliability and efficiency, oocyte cryopreservation allows young 
cancer patients to have their oocytes collected prior to the initiation of chemo- or 
radiotherapy for the treatment of various malignant diseases, with the expectation 
of having their oocytes fertilized after recovery [2, 3, 19, 20]. It also would permit 
healthy women to have their oocytes collected and preserved for use in the future 
[4, 7, 8, 16–18] and for donor oocyte bank establishment [24, 25, 33].
It has been found that live birth rate was reduced significantly in women 
>37 years old after fresh oocyte IVF and the reduced live birth rate was mainly 
caused by embryonic aneuploidies [34–37]. Therefore, women’s age at the time 
of oocyte cryopreservation is the most important factor affecting live birth rates. 
Present and previous data [3, 9, 16–18] suggest that women should preserve their 
oocytes before 37 years old if they plan to rely on oocyte cryopreservation to have a 
live birth. However, for the women who are more than 37 years old, it is still possible 
to have their oocytes to be cryopreserved for future use, but success mainly relies on 
oocyte quality and number [3, 9, 13].
In the present study, when we analyzed the efficiency of oocyte cryopreservation 
in women at different age groups, we found that live birth rates can reach to 51.1, 
46.7 and 28.6% in women <35, 35–37, and > 37 years old, respectively, with their first 
embryo transfer (fresh), which is comparable to live birth rates with embryo transfer 
from fresh oocytes in our clinic or other published data [2, 3, 9, 23, 25]. A decreased 
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tendency in live birth rate was observed in women >37 years as compared with women 
≤37 years old. This is true because embryo quality (competence to develop to blasto-
cysts and chromosome status) decreases when women reach >37 years old [37, 38]. 
Even when high quality blastocysts were transferred, embryo implantation rates also 
dropped, which eventually reduced live birth rates. Furthermore, morphological 
assessment of embryos does not always choose chromosomally normal embryos, thus 
high miscarriage rates were found in this population [35, 36]. In the present study, most 
patients had fresh blastocyst transfer without PGT-A. Actually frozen/warmed euploid 
blastocyst transfer after PGT-A did not further increase embryo implantation in all age 
groups in the present study. Similar outcomes have recently been found when embryos 
(with or without PGT-A) from fresh oocytes were transferred [39, 40], especially 
the benefits of PGT-A were not found in patients <37 years old. However, large data 
analysis of pregnancy outcomes in women aged 35–40 years demonstrated a significant 
improvement in clinical pregnancy rate and live birth rate with the use of PGT-A per 
embryo transfer [41]. Thus, it is difficult to explain the differences between reports.
Cancelation is very common in human ART, especially in poorly responding and/
or older patients. In the present study, we cultured all embryos to Days 5–7 to allow 
embryos to develop to blastocyst stage and found that more patients >37 years old 
had to cancel embryo transfer due to lack of blastocyst development than patients 
<35 years old, and this indicates that oocyte quality in older patients are poorer than 
that in young patients. Although number of oocytes is also a reason for cancelation of 
a cycle, oocyte quality may be the main reason. Other factors should also be consid-
ered as the reasons for cancelation. For example, some canceled cycles had previous 
failed IVF cycles with the same cohort of fresh oocytes or had failed cycles due to 
severe male factor infertility. From laboratory results, it was found that no fertiliza-
tion (mainly due to male factor infertility) and no embryo cleavage also caused cycle 
cancelation. Therefore, the reason(s) for cycle cancelation is complicated and multi-
ple factors should be considered to explain the cause of failed blastocyst development.
Blastocyst transfer has been one of the most practical embryo selection strate-
gies in human ART [42, 43], which could reduce number of embryos to be trans-
ferred and multiple pregnancy [43–45]. Our clinic has adopted blastocyst transfer 
for all patients, even in patients with a limited number of oocytes. However, we 
still do not know if pregnancy can be improved by early-stage embryo transfer for 
oocyte warming cycles. As some fertilized oocytes (as high as 10%) did not cleave 
during the culture, it is unknown whether embryo development arrest can be over-
come by transferring early stage of embryos to uterus. It would also be possible that 
embryo arrest is caused by damages of some intra-oocyte structures during oocyte 
cryopreservation and warming, as embryo arrest is less than 1% in human IVF with 
fresh oocytes in our laboratory. Thus, current oocyte cryopreservation and warm-
ing technology needs further improving.
In the present study, we also found that average birth weight and proportions of 
babies with low birth weight after fresh embryo transfer were comparative to aver-
age weight of babies from fresh oocytes [42, 45, 46]. However, low birth weight 
was observed in babies from frozen/warmed blastocyst transfer in the present 
study although there are no statistical differences as compared with babies from 
fresh blastocyst transfer. This is certainly different from those with fresh oocyte 
IVF in which birth weights were higher in babies from FET than babies from fresh 
embryo transfer [47]. Because this is the first time that we noticed the difference 
in birth weight between fresh blastocyst transfer and frozen/warmed blastocyst 
transfer from frozen/warmed oocytes and the case number is also very limited, 
further data collection is necessary to reveal whether low birth weight after 
transfer of frozen/warmed blastocysts resulting from frozen/warmed oocytes is a 
common phenomenon.
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Oocyte cryopreservation has been widely provided to women for various 
purposes. In the present study, we found that the efficiency was different among 
three different patient categories. Women used oocyte cryopreservation as fertil-
ity preservation had higher live birth rate as compared with patients who initially 
underwent infertility treatment. For infertility patients, live birth rates between 
partial oocyte cryopreservation/warming and all oocyte cryopreservation/warming 
were not significantly different although fewer oocytes had less opportunity to have 
a live birth, which was similar as that predicted by other researchers [3], especially 
when cumulated live birth rates were calculated [9].
However, for patient own oocytes, there are many factors, such as age and ovar-
ian and hormone status. Some patients with oocyte cryopreservation may be due to 
lack of (enough) sperm for insemination, thus the time for oocyte cryopreservation 
may be delayed (after insemination of partial oocytes or after waiting for attempt 
of sperm collection). Occyte cryopreservation is usually performed 3–5 h after egg 
retrieval [2, 9, 11], thus it is still unknown whether delayed cryopreservation affects 
oocyte survival, fertilization, and embryo development. We did not examine these 
factors in the present study because the case numbers are very small in each cat-
egory. For these patients, male factor infertility may also affect oocyte fertilization 
and embryo development and implantation.
We found that embryo development is slower with frozen oocytes as com-
pared with fresh oocytes. Recently, Cobo et al. used time-lapse scope to track 
oocyte fertilization and embryo development, they found that pronuclear 
formation is about 1 h delayed in frozen oocytes as compared with fresh oocytes 
[48]. We also found that Day 5 blastocyst rates were lower but overall blastocyst 
rates (Days 5–7) were same between fresh and frozen donor oocytes in a previous 
study [11, 49].
A comprehensive analysis should be done whether an oocyte warming cycle 
can eventually result in a live birth. Many factors, such as oocyte quality, numbers 
of oocytes warmed, previous IVF outcomes, male factor infertility and others, 
should be carefully evaluated because women will rely on cryopreserved oocyte 
IVF to have a live birth in the future. It should be realized that if a fresh oocyte 
IVF cycle fails (no embryo available for transfer after IVF or no live birth after 
embryo transfer), the patients can attempt the second or more cycles to achieve 
a live birth. However, if an oocyte warming cycle fails to have a live birth, it 
may be too late for the patients to attempt the second or more oocyte retrieval 
cycles, especially when women use oocyte cryopreservation as their fertility 
preservation.
5. Conclusions
In conclusion, many factors affect the successful application of oocyte cryo-
preservation for women who want to preserve their fertility. Women’s age at the 
time of oocyte cryopreservation is one of the most important factors to consider. 
Based on our current and previously published data, we can conclude that oocyte 
cryopreservation for fertility preservation can be done at any time during a woman’s 
reproductive age. Similar as fresh oocyte IVF, the overall efficiency of oocyte cryo-
preservation is dependent up on women’s age and reproductive health at the time of 
oocyte cryopreservation.
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